

HCV in Kentucky

Danielle Revert, MSN, APRN, NP-C


Access to Care

- Transient population
- Decentralizing services to meet needs
- Partnering with local health systems
- Telemedicine to expand reach


Applegate TL, Fajardo E, Sacks JA. Hepatitis C virus diagnosis and the holy grail. Infect Dis Clin North Am. 2018;32(2):425-445.



Geographic Location of patients



Disease Progression



- Most patients will develop chronic HCV
- ~20% of patient will go on to develop cirrhosis (with HCV alone)
- Cirrhosis can progress on to end stage liver disease and liver cancer
- HCV is the #1 cause of liver cancer in the US
- There is no vaccine for HCV

Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(Suppl 1):S58-S68.

Extrahepatic Manifestations

- Lymphoma
- Diabetes
- Insulin Resistance
- Fatigue
- Depression
- Cognitive Impairment
- Cardiovascular Disease
- Renal Disease
- Cryoglobulinemia
- Dermatologic Issues
- Corneal Ulcers



- Hypothyroidism
- Weakness
- Arthritis/Joint pain
- Neuropathies

Kuna L, Jakab J, Smolic R, Wu GY, Smolic M. HCV extrahepatic manifestations. J Clin Transl Hepatol 2019;7(2):172–182. doi: 10.14218/JCTH.2018.00049.



Early treatment

- Prevents the development of severe liver disease
 - Improved survival and quality of life
- Patients are easier to cure if you treat them early
 - Treatment is only 8-12 weeks and has 98% cure rate
- Financials
 - “Annual per-person Medicaid healthcare costs attributed to HCV infection were estimated to range from **\$10,561** for noncirrhotic adults to **\$46,263** for adults with end-stage liver disease.”
 - Cured patients avoid an estimated annual **\$15,907** in healthcare costs
 - Treatment costs have dropped 78% since 2014
- Treatment as prevention



- AASLD. (n.d.). *When and in whom to initiate hcv therapy: Hcv guidance*. When and in Whom to Initiate HCV Therapy | HCV Guidance. <https://www.hcvguidelines.org/evaluate/when-whom>.
- Backus LI, Belperio PS, Shahoumian TA, Mole LA. Direct-acting antiviral sustained virologic response: impact on mortality in patients without advanced liver disease. *Hepatology*. 2018;68(3):827-838.
- Backus LI, Belperio PS, Shahoumian TA, Mole LA. Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. *Hepatology*. 2019;69(2):487-4
- Fagundes RN, Ferreira LEVVC, Pace FHL. Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with directacting antivirals agents interferon-free. *PLoS One*. 2020;15(8):e0237005.
- Mohanty A, Salameh S, Butt AA. Impact of Direct Acting Antiviral Agent Therapy upon Extrahepatic Manifestations of Hepatitis C Virus Infection. *Curr HIV/AIDS Rep*. 2019 Oct;16(5):389-394. doi: 10.1007/s11904-019-00466-1. PMID: 31482299.